Clinical trials
Observational Inflammation trials in Germany
Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.
33 trials match Source: ClinicalTrials.gov registrations
Trials started per year
By phase, 2000 to 2026.
| Category | Trials |
|---|---|
| 2002 | 1 |
| 2003 | 1 |
| 2005 | 1 |
| 2007 | 3 |
| 2008 | 2 |
| 2009 | 2 |
| 2010 | 2 |
| 2011 | 4 |
| 2012 | 4 |
| 2013 | 1 |
| 2015 | 2 |
| 2016 | 2 |
| 2018 | 1 |
| 2020 | 1 |
| 2022 | 3 |
| 2024 | 3 |
Status
Trials by registry status. Select a bar to filter.
| Category | Trials |
|---|---|
| Completed | 18 |
| Unknown status | 8 |
| Recruiting | 6 |
| Active, not recruiting | 1 |
Top lead sponsors
A sponsor with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Johann Wolfgang Goethe University Hospital | 8 |
| University of Ulm | 4 |
| Technical University of Munich | 2 |
| University Hospital Tuebingen | 2 |
| Charite University, Berlin, Germany | 1 |
| German Federal Institute for Risk Assessment | 1 |
| Heart Center Leipzig - University Hospital | 1 |
| Heart and Diabetes Center North-Rhine Westfalia | 1 |
| Heidelberg University | 1 |
| Jena University Hospital | 1 |
Top conditions
MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Inflammation | 33 |
| Sepsis | 5 |
| Bronchiolitis Obliterans | 4 |
| Infections | 4 |
| Obesity | 4 |
| Heart Failure | 3 |
| Multiple Trauma | 3 |
| Shock | 3 |
| Systemic Inflammatory Response Syndrome | 3 |
| Cardiovascular Diseases | 2 |
Trials
Showing 1 to 25 of 33. Each trial links to its page on Pharma Observatory.
Recently changed trials
Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.
No changes to these trials in the last 7 days.
Go deeper on Pharma Observatory
Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.